Cambridge Epigenetix announces $21M Series B financing and appoints Dr Geoff Smith as CEO

Fundraise will support commercial expansion and translational product development

Cambridge, UK – March 14, 2016 – Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, today announced the close of a $21 million Series B financing and the appointment of Dr. Geoff Smith as CEO. The round was led by GV (formerly Google Ventures), with significant participation from Sequoia Capital. Current investors New Science Ventures, Syncona Partners and Cambridge University also joined the round. In conjunction with the fundraising, Tom Hulme, GV general partner, will join CEGX’s board of directors and co-founder Dr. Bobby Yerramilli-Rao will assume the role of Chairman.

Read more here.




Come and work for CEGX



Latest News

Exciting new study on DNA methylation and gene expression dynamics...

Researchers from Hiroyuki Sasaki’s lab published a breakthrough study on the regulation of spermatogonial stem cell formation and differentiation. Kubo et al. show distinct and dynamic regulation of DNA methylation during spermatogonial stem cell formation and differentiation in the neonatal and...